Chemed (CHE) EBITDA (2009 - 2026)

Chemed's EBITDA history runs 18 years deep, the most recent figure standing at $98.9 million for Q1 2026.

• In Q1 2026, EBITDA fell 8.62% year-over-year to $98.9 million; the TTM figure through Mar 2026 stood at $383.5 million (down 13.23% YoY), while the FY2025 annual figure was $392.8 million, down 6.33% from the prior year.
• EBITDA was $98.9 million for Q1 2026 at Chemed, down from $114.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $127.1 million in Q4 2024 to a low of -$180.8 million in Q4 2022.
• Historically, EBITDA has averaged $83.6 million across 5 years, with a median of $99.7 million in 2023.
• Biggest YoY gain for EBITDA was 168.8% in 2023; the steepest drop was 21.51% in 2023.
• A 5-year view of EBITDA shows it stood at -$180.8 million in 2022, then jumped by 168.8% to $124.4 million in 2023, then grew by 2.19% to $127.1 million in 2024, then fell by 10.01% to $114.4 million in 2025, then retreated by 13.58% to $98.9 million in 2026.
• The last three EBITDA figures came in at $98.9 million (Q1 2026), $114.4 million (Q4 2025), and $88.4 million (Q3 2025), per Business Quant data.